GlassScriptPhysician profile
David Thayer Kyle
NPI 1235820747
$5,439.50
in general payments reported to CMS, 2019-2025
35 companies · $2,746 in 2025
The $2,746 reported for 2025 was more than what 96% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $689 · 2024: $2,004 · 2025: $2,746.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,440.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,439.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $908.84 | 2023-2025 | Briviact, Zilbrysq, Nayzilam |
| Abbvie INC. | $763.34 | 2023-2025 | |
| Neurocrine Biosciences, INC. | $396.88 | 2023-2025 | Ingrezza, Ongentys |
| Pfizer INC. | $372.32 | 2023-2025 | |
| Celgene Corporation | $368.32 | 2023-2024 | Zeposia |
| Lundbeck LLC | $333.27 | 2023-2025 | Vyepti, Rexulti |
| Argenx US, INC. | $295.92 | 2024-2025 | Vyvgart Hytrulo, Vyvgart |
| Biogen, INC. | $266.21 | 2024-2025 | Tysabri, Vumerity, Spinraza |
| Neurelis, INC. | $221.32 | 2024-2025 | Valtoco |
| Catalyst Pharmaceuticals, INC. | $129.10 | 2024-2025 | |
| Teva Pharmaceuticals USA, INC. | $119.59 | 2024-2025 | Austedo Xr, Ajovy, Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $109.14 | 2023-2025 | Nuedexta, Rexulti |
| Alexion Pharmaceuticals, INC. | $95.33 | 2025 | Ultomiris |
| Axsome Therapeutics, INC. | $90.64 | 2025 | Symbravo |
| Ani Pharmaceuticals, INC. | $85.62 | 2024-2025 | Purified Cortrophin Gel |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mdd US Operations, LLC | $81.44 | 2025 | Gocovri, Qelbree |
| Jazz Pharmaceuticals INC. | $79.17 | 2025 | |
| Genentech USA, INC. | $78.58 | 2023-2024 | Ocrevus, Enspryng |
| Csl Behring | $73.99 | 2023-2024 | Hizentra |
| Vanda Pharmaceuticals INC. | $69.61 | 2025 | Ponvory |
| Scilex Pharmaceuticals INC. | $68.46 | 2024-2025 | |
| Amneal Pharmaceuticals LLC | $66.62 | 2023-2025 | Rytary, Crexont |
| Amgen INC. | $60.40 | 2024-2025 | Uplizna |
| Sk Life Science, INC. | $51.09 | 2024-2025 | |
| Boston Scientific Corporation | $39.17 | 2025 | General - Dbs |
| Cala Health, INC. | $33.42 | 2025 | Cala Kiq |
| Abbott Laboratories | $32.24 | 2023-2025 | Amplatzer Talisman, Proclaim |
| Microtransponder, INC. | $23.74 | 2025 | |
| Novartis Pharmaceuticals Corporation | $22.33 | 2025 | |
| Lilly USA, LLC | $19.73 | 2023 | Amyvid |
| Octapharma USA, INC. | $18.05 | 2023 | Panzyga |
| Eisai INC. | $17.64 | 2025 | |
| Kyowa Kirin, INC. | $17.46 | 2024 | Nourianz |
| Livanova USA, INC. | $16.44 | 2024 | Vns Therapy Sentiva Model 1000 Generator |
| Grifols USA, LLC | $14.08 | 2025 | Gamunex-C |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Kyle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.